Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.

Pérez C, Pascual M, Martín-Subero JI, Bellosillo B, Segura V, Delabesse E, Álvarez S, Larrayoz MJ, Rifón J, Cigudosa JC, Besses C, Calasanz MJ, Cross NC, Prósper F, Agirre X.

Haematologica. 2013 Sep;98(9):1414-20. doi: 10.3324/haematol.2013.084160. Epub 2013 May 28.

2.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
3.

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.

Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski JP, Melnick AM, Greally JM, Steidl U, Moliterno A, Verma A.

Cancer Res. 2013 Feb 1;73(3):1076-85. doi: 10.1158/0008-5472.CAN-12-0735. Epub 2012 Oct 11.

4.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
5.

Calcitonin gene methylation in chronic myeloproliferative disorders.

Ihalainen J, Juvonen E, Savolainen ER, Ruutu T, Palotie A.

Leukemia. 1994 Feb;8(2):230-5.

PMID:
8309247
6.

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR.

Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591. Epub 2011 Jun 28.

7.

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Andrikovics H, Krahling T, Balassa K, Halm G, Bors A, Koszarska M, Batai A, Dolgos J, Csomor J, Egyed M, Sipos A, Remenyi P, Tordai A, Masszi T.

Haematologica. 2014 Jul;99(7):1184-90. doi: 10.3324/haematol.2014.107482. Epub 2014 Jun 3.

8.

[Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].

Tovar-Bobadilla JL, Ortiz-Hidalgo C.

Gac Med Mex. 2016 May-Jun;152(3):407-18. Review. Spanish.

9.

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC.

Leuk Lymphoma. 2012 Jan;53(1):123-9. doi: 10.3109/10428194.2011.597905. Epub 2011 Aug 1.

PMID:
21806350
10.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092
11.

Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms.

Chim CS, Wan TS, Fung TK, Wong KF.

J Clin Pathol. 2010 Oct;63(10):942-6. doi: 10.1136/jcp.2010.080218. Epub 2010 Jul 29.

PMID:
20671051
12.

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Pikman Y, Levine RL.

Curr Opin Oncol. 2007 Nov;19(6):628-34. Review.

PMID:
17906464
13.

Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Lieu CH, Shen YJ, Lai WC, Tsai WH, Hsu HC.

J Chin Med Assoc. 2010 Oct;73(10):530-2. doi: 10.1016/S1726-4901(10)70115-5.

14.
15.

Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation.

Barrio S, Gallardo M, Albizua E, Jimenez A, Rapado I, Ayala R, Gilsanz F, Martin-Subero JI, Martinez-Lopez J.

J Clin Pathol. 2011 Nov;64(11):1010-3. doi: 10.1136/jclinpath-2011-200175. Epub 2011 Aug 6.

PMID:
21821860
16.
17.

[New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].

Larsen TS, Pallisgaard N, Christensen JH, Gram-Hansen P, Kerndrup GB, Møller MB, Hasselbalch HC.

Ugeskr Laeger. 2006 Sep 25;168(39):3295-9. Review. Danish.

PMID:
17032591
18.

Molecular classification of myeloproliferative neoplasms-pros and cons.

Qureshi M, Harrison C.

Curr Hematol Malig Rep. 2013 Dec;8(4):342-50. doi: 10.1007/s11899-013-0179-9. Review.

PMID:
24091831
19.
20.

[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].

Andrikovics H, Szilvási A, Meggyesi N, Király V, Halm G, Lueff S, Nahajevszky S, Mikala G, Sipos A, Lovas N, Csukly Z, Mátrai Z, Tamáska J, Tordai A, Masszi T.

Orv Hetil. 2007 Feb 4;148(5):203-10. Hungarian.

PMID:
17344140

Supplemental Content

Support Center